TrialLeukemia2016
Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion.
A Toma et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
56 papers cite it
this paperpooled ittrialcites it